#PRTA

StockTitan

@stocktitan.net

2 weeks ago

Prothena Announces up to $100 Million Share Repurchase Plan Prothena (NASDAQ:PRTA) authorized a share repurchase plan to buy up to $100.0 million of its ordinary shares through December 31, 2026.The company reported $308.4 million in cash, cash equivalents and restricted cash and no debt as of December 31, 2025, and expects to end 2026 with about $255 million excluding repurchases and potential milestones. Prothena noted up to $105 million of potential 2026 clinical milestone payments from partners. Repurchases may occur in open market transactions, under Rule 10b-18, or via 10b5-1 plans, and may be suspended or discontinued at the company’s discretion.

#PRTA Prothena Announces up to $100 Million Share Repurchase Plan

www.stocktitan.net/news/PRTA/prothena-annou...

StockTitan

@stocktitan.net

4 months ago

#PRTA Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

www.stocktitan.net/news/PRTA/prothena-highl...

StockTitan

@stocktitan.net

4 months ago

#PRTA Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/PRTA/prothena-repor...

StockTitan

@stocktitan.net

6 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program Prothena (NASDAQ:PRTA) has announced results from its Phase 1 ASCENT clinical program for PRX012, their anti-amyloid beta antibody for early symptomatic Alzheimer's disease. The study demonstrated that PRX012 achieved dose- and time-dependent reductions in amyloid plaque, with the 400mg dose showing mean reduction to 27.47 centiloids at month 12.While PRX012 showed positive aspects including stable pharmacokinetics, low anti-drug antibodies, and low injection site reactions (4.1%), it demonstrated higher overall ARIA-E rates compared to FDA-approved anti-Aβ antibodies. Due to this non-competitive safety profile, Prothena plans to explore partnership opportunities to advance both PRX012 and its preclinical PRX012-TfR antibody variant.

#PRTA Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

www.stocktitan.net/news/PRTA/prothena-provi...

StockTitan

@stocktitan.net

7 months ago

Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential First-in-class amyloid depleter shows promise for fatal heart condition. Novo Nordisk advances Coramitug to Phase 3, unlocking potential $1.2B milestone deal. Learn more.

#PRTA Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

www.stocktitan.net/news/PRTA/prothena-annou...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Prothena Q2 Revenue Drops 97% | The Motley Fool

#PRTA #1ea9fbf2-956a-445a-aa30-9c2b4ba1a2f5 #data-news

Origin | Interest | Match

InsiderFinance

@insiderfinance.com

7 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#APLD, #NBIS, #PRTA, #PAGS, #NVST

#OptionFlow #OptionsTrading #Trading

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Small-cap stocks with declining money flow, Tue Jul 8th - #ULCC #RAPT #PRTA #MRKR #LTBR #KIRK #IKNA #GLRE #FDMT #EVAX #ONTH #STAA #TVNA #BLFS #BRCP #AYTU #ZEPP #VLRS #SEMR #OBK #LUXE #HBI #CHCG #REPL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

8 months ago

Prothena Announces Corporate Restructuring Prothena Corporation (PRTA) announced a significant corporate restructuring, including a 63% workforce reduction to optimize operating costs. The restructuring follows several key milestones, including Roche's advancement of prasinezumab to Phase 3 for early-stage Parkinson's disease, upcoming PRX012 Phase 1 data for Alzheimer's, and various partnered programs with potential milestone payments. The company revised its 2025 financial guidance, projecting a net cash burn of $170-178 million and year-end cash position of approximately $298 million. The expected 2025 net loss is estimated at $240-248 million, including $36 million in non-cash share-based compensation and $45 million non-cash tax expense. The discontinuation of birtamimab development is expected to reduce annualized net cash burn by approximately $96 million.

#PRTA Prothena Announces Corporate Restructuring

www.stocktitan.net/news/PRTA/prothena-annou...

InsiderFinance

@insiderfinance.com

8 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VALE, #HUYA, #FWRD, #PRTA, #STNE

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

8 months ago

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #VALE 5.4x
2. #HUYA 4.7x
3. #EOSE 3.6x
4. #FWRD 2.5x
5. #PRTA 2.4x

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

8 months ago

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease Prothena (NASDAQ:PRTA) announced that its partner Roche will advance prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease. The decision follows data from the Phase IIb PADOVA study and open-label extensions from both PADOVA and Phase II PASADENA studies. While prasinezumab showed potential clinical efficacy in reducing motor progression at 104 weeks, it missed statistical significance in the primary endpoint. The drug demonstrated positive trends that appear sustained over longer treatment periods, and provided first biomarker evidence of impact on underlying disease biology. The ongoing PASADENA and PADOVA OLE studies are evaluating long-term safety and efficacy in over 750 early-stage Parkinson's patients.

#PRTA Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

www.stocktitan.net/news/PRTA/prothena-s-par...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks gapping down in trading, Tue May 27th - #WTO #SGRP #QVCGP #SVRA #RCKT #PRTA #NPCE #MRIN #ZK - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

9 months ago

Prothena Halts AL Amyloidosis Drug After Phase 3 Failure, Announces Major Workforce Cuts Key trial missed mortality endpoint, forcing birtamimab discontinuation. Company plans substantial workforce reduction and cost cuts. See pipeline updates timeline.

#PRTA Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

www.stocktitan.net/news/PRTA/prothena-annou...

StockTitan

@stocktitan.net

10 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights Prothena Corporation (PRTA) reported Q1 2025 financial results with a net loss of $60.2 million ($1.12 per share) and revenue of $2.8 million. The company ended Q1 with $418.8 million in cash and restricted cash. Key upcoming milestones include: 1. Topline results expected in Q2 2025 from Phase 3 AFFIRM-AL trial of birtamimab for AL amyloidosis 2. Multiple clinical readouts for PRX012 (Alzheimer's treatment) starting mid-2025 3. Phase 2b PADOVA trial results for prasinezumab in Parkinson's disease showed possible benefits 4. Phase 2 trial results for coramitug in ATTR-CM expected in 2H 2025 The company projects 2025 net cash use of $168-175 million in operating and investing activities, with an estimated year-end cash position of approximately $301 million.

#PRTA Prothena Reports First Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/PRTA/prothena-repor...

StockTitan

@stocktitan.net

1 year ago

Can Prothena's $472M War Chest and Multiple 2025 Trial Results Transform Its Market Position? Prothena maintains robust $472M cash position while advancing multiple late-stage programs. Phase 3 AFFIRM-AL results expected Q2 2025, backed by BMS partnership.

#PRTA Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

www.stocktitan.net/news/PRTA/prothena-repor...

InsiderFinance

@insiderfinance.com

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PRTA, #AI, #UVIX, #CRC, #NXE

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

1 year ago

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SOUN, #AI, #JD, #IBIT, #PRTA

#OptionFlow #OptionsTrading #Trading

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #PRTA ) Sector Perform Recommendation Issued On PRTA By RBC Capital

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #PRTA ) Prothena Corp. (NASDAQ: PRTA) Near the Top of Equities by Percentage Gain on 12/19

#StockMarket #News

InsiderFinance

@insiderfinance.com

1 year ago

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PRTA 4.3x
2. #AI 2.9x
3. #UVIX 2.7x
4. #HIMS 2.4x
5. #CRC 2.3x

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

1 year ago

Prothena's Parkinson's Drug Shows Promise in Phase IIb Trial Despite Missing Primary Endpoint Roche's prasinezumab demonstrates potential benefits in early-stage Parkinson's, with significant motor progression delay in levodopa patients despite mixed trial results.

#PRTA Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

www.stocktitan.net/news/PRTA/roche-s-phase-...